Profilo committente
HUS Group, the joint authority for Helsinki and Uusimaa
FI- Aggiudicazioni
- 18
- Valore totale aggiudicato
- 104.066.856 €
- Paesi
- countries.FI
- Ultima aggiudicazione
- 15 mag 2026
- In scadenza entro 12 mesi
- 3
Storico delle aggiudicazioni
| Data | Fornitore | Titolo | Categoria | Importo | Paese | Scadenza | Fonte |
|---|---|---|---|---|---|---|---|
| 15/05/2026 | BeOne Medicines, GmbH, Dutch Branch | Finland – Pharmaceutical products – Tislelitsumabin (Tevimbra) hankinta | — | 1,0 Mln € | FI | 31/12/2026 | Vedi su TED ↗ |
| 11/03/2026 | MSD Finland Oy | Finland – Pharmaceutical products – Sotaterseptivalmisteen (Winrevair) hankinta | — | 500,0K € | FI | 31/12/2026 | Vedi su TED ↗ |
| 09/02/2026 | Recordati AB | Finland – Pharmaceutical products – Osilodrostaatin (Isturisa 1 mg, 5 mg ja 10 mg) hankinta | — | 600,0K € | FI | 31/12/2026 | Vedi su TED ↗ |
| 18/11/2025 | Oy Bristol Myers Squibb (Finland) Ab | Finland – Pharmaceutical products – CAR-T-soluterapiavalmisteet hankintakaudelle 1.1.2026 – 31.12.2027 | — | 20,0 Mln € | FI | 31/12/2027 | Vedi su TED ↗ |
| 27/08/2025 | Sanofi Oy | Finland – Pharmaceutical products – Nirsevimabin (Beyfortus 50 mg ja 100 mg injektioneste, liuos, esitäytetty ruisku) hankinta RSV-kaudelle 2025-2026 | — | 10,5 Mln € | FI | 31/03/2026 | Vedi su TED ↗ |
| 14/04/2025 | Novartis Finland Oy | Finland – Pharmaceutical products – Tisagenlekleuseeli (Kymriah) lapsipotilaille tai korkeintaan 25 vuoden ikäisille nuorille aikauispotilaille | — | 4,5 Mln € | FI | 31/12/2025 | Vedi su TED ↗ |
| 03/03/2025 | Ascendis Pharma A/S | Finland – Pharmaceutical products – Palopegteriparatidivalmisteen (Yorvipath) hankinta | — | 700,0K € | FI | 31/12/2025 | Vedi su TED ↗ |
| 10/02/2025 | Gilead Sciences Finland Oy | Finland – Antineoplastic and immunomodulating agents – CAR-T-soluterapiavalmisteet hankintakaudelle 1.1.2025 – 31.12.2025 | — | 33,0 Mln € | FI | 31/12/2025 | Vedi su TED ↗ |
| 10/02/2025 | Immunocore Ireland Ltd | Finland – Pharmaceutical products – Tebentafuspivalmisteen (Kimmtrak 100 mikrogrammaa/0,5 mlinfuusiokonsentraatti, liuosta varten) hankinta | — | 3,1 Mln € | FI | — | Vedi su TED ↗ |
| 14/01/2025 | Biogen Finland Oy | Finland – Pharmaceutical products – Nusinerseenivalmisteen (Spinraza 12 mg injektioliuos) hankinta | — | 1,0 Mln € | FI | — | Vedi su TED ↗ |
| 14/01/2025 | Janssen-Cilag Oy | Finland – Pharmaceutical products – Talketamabivalmisteen (Talvey) hankinta | — | 260,0K € | FI | 31/12/2025 | Vedi su TED ↗ |
| 13/01/2025 | Gilead Sciences Finland Oy | Finland – Pharmaceutical products – Breksukabtageeni autoleuseeli -valmisteen (Tecartus® 0,4 – 2 × 108 solua infuusioneste, dispersio) hankinta | — | 3,0 Mln € | FI | 31/12/2025 | Vedi su TED ↗ |
| 27/08/2024 | Sanofi Oy | Finland – Pharmaceutical products – Nirsevimabin (Beyfortus 50 mg ja 100 mg injektioneste, liuos, esitäytetty ruisku) hankinta RSV-kaudelle 2024-2025 | — | 14,0 Mln € | FI | — | Vedi su TED ↗ |
| 28/05/2024 | Bio-Rad Finland Oy | Finland – Chemical reagents – Quality Assurance samples and Calibrators for HUS Laboratory of Endocrinology and Metabolism | — | 306,9K € | FI | — | Vedi su TED ↗ |
| 02/05/2024 | Oy Bristol Myers Squibb (Finland) Ab | Finland – Medical equipments, pharmaceuticals and personal care products – Nivolumabin ja relatlimabin yhdistelmävalmisteen hankinta | — | 1,4 Mln € | FI | 31/12/2025 | Vedi su TED ↗ |
| 29/02/2024 | Gilead Sciences Finland Oy | Finland – Antivirals for systemic use – Bulevirtidivalmiste (Hepcludex® 2 mg injektiokuiva-aine) suorahankinta | — | 1,2 Mln € | FI | 31/12/2024 | Vedi su TED ↗ |
| 28/02/2024 | Gilead Sciences Finland Oy | Finland – Pharmaceutical products – Remdesiviirin (Veklury 100 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos) suorahankinta | — | 1,0 Mln € | FI | 31/12/2024 | Vedi su TED ↗ |
| 28/02/2024 | Pfizer Oy | Finland – Pharmaceutical products – Nirmatrelviirin ja ritonaviirin yhdistelmävalmisteen (PAXLOVID tabletti, kalvopäällysteinen 150 mg + 100 mg) suorahankinta | — | 8,0 Mln € | FI | 31/12/2024 | Vedi su TED ↗ |